Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 8/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19582241 | 0.86 | ACKR3 (0.43) | CYP1A2CYP2D6CYP2C19ACKR3 | |
| SCHEMBL17801978 | 0.84 | ACKR3 (0.40) | KMT2ACYP1A2CYP2D6CYP2C19ACKR3 | |
| SCHEMBL20873632 | 0.76 | ACKR3 (0.39) | MAPTACKR3 | |
| SCHEMBL17801970 | 0.75 | MAPT (0.39) | KMT2ALMNAMAPTCYP1A2CYP2C19 | |
| SCHEMBL8331252 | 0.75 | MAPT (0.45) | KMT2ALMNAMAPTCYP1A2CYP2C19 | |
| SCHEMBL19582451 | 0.74 | MAPT (0.41) | KMT2ALMNAMAPTCYP1A2CYP2C19 | |
| SCHEMBL8948801 | 0.74 | PARP1 (0.49) | KMT2AMAPT | |
| SCHEMBL10659420 | 0.71 | ALDH1A1 (0.42) | KMT2AMAPTCHRNB4CHRNA3MEN1 | |
| SCHEMBL20873625 | 0.71 | LMNA (0.38) | KMT2ALMNAMAPTCHRNB4CHRNA3 | |
| SCHEMBL17801966 | 0.70 | ACKR3 (0.56) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001279-B | CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2020-10-20 | — | — | CN | disclosed |
| EP-3227263-B1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-10 | — | — | EP | disclosed |
| US-10202368-B2 | CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2019-02-12 | — | — | US | disclosed |
| US-20170327493-A1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-16 | — | — | US | disclosed |
| EP-3227263-A1 | CXCR7 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd (CH) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016087370-A1 | CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202368-B2 | CXCR7 receptor modulators | CXCR1, CXCR5, CXCR2 | KMT2A 4322/4885LMNA 4407/4885MAPT 4603/4885 |
| US-20170327493-A1 | CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, CXCR2 | KMT2A 4313/4885LMNA 3981/4885MAPT 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.